MediWound (NASDAQ:MDWD) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

MediWound Ltd. (NASDAQ:MDWD)’s stock price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $16.26 and traded as low as $14.40. MediWound shares last traded at $14.62, with a volume of 46,085 shares trading hands.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of MediWound in a report on Thursday, May 28th. Oppenheimer reaffirmed an “outperform” rating and set a $32.00 price objective (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, MediWound has an average rating of “Hold” and a consensus target price of $34.00.

MediWound Trading Down 1.8%

The stock has a market cap of $181.12 million, a price-to-earnings ratio of -6.24 and a beta of 0.14. The company’s fifty day moving average is $14.53 and its two-hundred day moving average is $16.19.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.42. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $3.37 million. During the same period in the prior year, the firm posted ($0.07) EPS. Analysts predict that MediWound Ltd. will post -2.31 EPS for the current year.

Insider Buying and Selling at MediWound

In related news, Director David Morton Fox purchased 3,537 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was purchased at an average cost of $14.11 per share, with a total value of $49,907.07. Following the completion of the acquisition, the director directly owned 22,283 shares in the company, valued at $314,413.13. This trade represents a 18.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 9.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MDWD. Quarry LP purchased a new position in MediWound in the 4th quarter valued at about $26,000. BNP Paribas Financial Markets raised its stake in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares during the period. Russell Investments Group Ltd. raised its stake in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in shares of MediWound during the 4th quarter valued at $109,000. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.